Stockscreener 앱 받기
5.70
1.72%
-0.10
전일 마감가:
$5.80
열려 있는:
$5.82
하루 거래량:
1.77M
Relative Volume:
0.83
시가총액:
$1.01B
수익:
-
순이익/손실:
$-45.44M
주가수익비율:
-16.29
EPS:
-0.35
순현금흐름:
$-42.28M
1주 성능:
+6.54%
1개월 성능:
+8.78%
6개월 성능:
+82.11%
1년 성능:
+128.00%
1일 변동 폭
$5.55
$5.85
1주일 범위
$5.085
$6.25
52주 변동 폭
$1.33
$6.25
Compass Therapeutics Inc Stock (CMPX) Company Profile
명칭
Compass Therapeutics Inc
전화
617-500-8099
주소
80 GUEST STREET, BOSTON
CMPX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
5.70 | 1.03B | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-05 | 개시 | William Blair | Outperform |
| 2025-12-03 | 개시 | Canaccord Genuity | Buy |
| 2025-12-03 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-12-03 | 개시 | Citizens JMP | Mkt Outperform |
| 2025-07-01 | 재개 | Raymond James | Outperform |
| 2025-04-02 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-02-24 | 개시 | Guggenheim | Buy |
| 2025-02-19 | 개시 | Piper Sandler | Overweight |
| 2024-12-23 | 개시 | D. Boral Capital | Buy |
| 2024-11-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2023-01-31 | 개시 | Jefferies | Buy |
| 2023-01-27 | 개시 | Stifel | Buy |
| 2022-05-23 | 재개 | H.C. Wainwright | Buy |
| 2022-03-15 | 개시 | Ladenburg Thalmann | Buy |
| 2022-01-19 | 개시 | B. Riley Securities | Buy |
| 2021-12-22 | 개시 | Raymond James | Outperform |
| 2021-12-20 | 개시 | SVB Leerink | Outperform |
| 2021-12-15 | 개시 | Wedbush | Outperform |
모두보기
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
Assessing Compass Therapeutics (CMPX) Valuation After Strong 1 Year Share Price Performance - Yahoo Finance
Aug Catalysts: How does Compass Therapeutics Inc perform in inflationary periods2025 Buyback Activity & Risk Managed Trade Strategies - baoquankhu1.vn
Is Compass Therapeutics (CMPX) Quietly Rewriting Its Oncology Strategy With New Commercial and Medical Chiefs? - Yahoo Finance
Compass Therapeutics (NASDAQ:CMPX) Trading Down 6.8%Time to Sell? - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Sets New 12-Month HighTime to Buy? - MarketBeat
Compass Therapeutics Inc. (CMPX) is A Buy on Wall Street on Robust Pipeline Development - MSN
Growth Review: Is Compass Therapeutics Inc stock a top pick in earnings seasonJuly 2025 Summary & Community Consensus Trade Alerts - Bộ Nội Vụ
Lifesci Capital Has Strong Estimate for CMPX FY2025 Earnings - Defense World
What is Lifesci Capital's Estimate for CMPX FY2025 Earnings? - MarketBeat
Why Compass Therapeutics Inc. stock could outperform in 2025Market Trend Report & Scalable Portfolio Growth Ideas - Улправда
Will Compass Therapeutics Inc. stock benefit from green energy trendsQuarterly Profit Summary & Low Drawdown Momentum Ideas - ulpravda.ru
Is Compass Therapeutics Inc. stock affected by interest rate hikesJuly 2025 Rallies & Capital Protection Trading Alerts - Улправда
Short Squeeze: Is Compass Therapeutics Inc. stock supported by strong fundamentalsWeekly Trade Review & Daily Volume Surge Signals - Улправда
Will Compass Therapeutics Inc. stock benefit from commodity prices2025 Fundamental Recap & Weekly Breakout Watchlists - Улправда
How Compass Therapeutics Inc. stock reacts to global recession fearsEarnings Performance Report & Real-Time Buy Signal Notifications - Улправда
Is Compass Therapeutics Inc. stock a defensive play in 20252025 Pullback Review & Long-Term Growth Portfolio Plans - Улправда
Is Compass Therapeutics Inc. stock supported by strong fundamentals2025 Technical Patterns & Free Expert Verified Stock Movement Alerts - Улправда
Compass Therapeutics, Inc. (CMPX) Stock Analysis: Exploring a Biotech Powerhouse with 142.77% Upside Potential - DirectorsTalk Interviews
Why analysts remain bullish on Compass Therapeutics Inc. stock2025 Investor Takeaways & Reliable Entry Point Alerts - ulpravda.ru
Is Compass Therapeutics Inc. stock in correction or buying zoneMarket Capitalization Trends & Reinvest for Maximum Compounding Returns - Улправда
Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - Benzinga
Compass Therapeutics stock rating reiterated at Market Outperform by Citizens - Investing.com Canada
Compass Therapeutics details cash runway and pipeline progress - MSN
Compass Therapeutics (NASDAQ:CMPX) Receives “Buy” Rating from D. Boral Capital - Defense World
Compass Therapeutics appoints new chief commercial and medical officers By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Compass Therapeutics stock with $12 target - Investing.com Canada
Raymond James reiterates Outperform rating on Compass Therapeutics stock By Investing.com - Investing.com Canada
Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Compass Therapeutics reports progress across cancer drug pipeline By Investing.com - Investing.com South Africa
Compass Therapeutics Provides Corporate Update - The Manila Times
Compass Therapeutics reports progress across cancer drug pipeline - Investing.com
CMPXCompass Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Compass Therapeutics, Inc. Announces Executive Appointments, Effective as of January 1, 2026 - marketscreener.com
William Blair Initiates Coverage of Compass Therapeutics (CMPX) with Outperform Recommendation - Nasdaq
Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care - One News Page
Compass Therapeutics announces key leadership appointments - marketscreener.com
Compass Therapeutics appoints new chief commercial and medical officers - Investing.com
Compass Therapeutics Announces Key Leadership Appointments - The Manila Times
William Blair Initiates Compass Therapeutics at Outperform - MarketScreener
William Blair initiates coverage on Compass Therapeutics stock with Outperform rating - Investing.com Canada
Which Way Will The Needle Swing For Compass Therapeutics' Biliary Tract Cancer Study? - RTTNews
Guggenheim Initiates Coverage of Compass Therapeutics (CMPX) with Buy Recommendation - MSN
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5%What's Next? - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5% – What’s Next? - Defense World
Compass Therapeutics files for up to $400 million mixed shelf offeringSEC filing - marketscreener.com
Compass Therapeutics Files $400 Million Mixed Shelf - MarketScreener
Wedbush Remains a Buy on Compass Therapeutics (CMPX) - The Globe and Mail
Compass Therapeutics’ (CMPX) Tovecimig Drives Strong Analyst Sentiment - Insider Monkey
Compass Therapeutics' (CMPX) Tovecimig Drives Strong Analyst Sentiment - Finviz
Compass Therapeutics Inc (CMPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Compass Therapeutics Inc 주식 (CMPX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
| ORBIMED ADVISORS LLC | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
4.73%
0.92%
자본화:
|
볼륨(24시간):